In 5-Year Span of FDA Accelerated Approvals in Cancer, 43% Show Confirmatory Clinical Benefit

Fifty-seven percent of drugs granted accelerated approval for a cancer indication showed clinical benefit in confirmatory studies.

Related Keywords

San Diego ,California ,United States ,Philadelphia ,Pennsylvania ,American ,Selpercatinib Retevmo ,Edwardrs Cliff ,Bosutinib Bosulif ,Capmatinib Tabrecta ,Asciminib Scemblix ,Program On Regulation ,Harvard Medical School ,American Association For Cancer Research ,Than Half ,Confirmatory Trials After Five ,American Association ,Published April ,